Caricamento...
Venetoclax-containing regimens in acute myeloid leukemia
Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML). Notably, the safety profile of venetoclax-based induction regimens was favorable, with a l...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7882757/ https://ncbi.nlm.nih.gov/pubmed/33628408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720986646 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|